[ad_1]
In Rawai Merck Friday said it was completed Previously Announced Acquisitions of Ophthalmic Biotechnology Co., Ltd. An upfront payment of $1.3 billion is required, with additional milestone payments of up to $1.7 billion.
EyeBio is now a wholly owned subsidiary of Merck.
“The acquisition of EyeBio diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases,” said Dean Y. Li, president of Merck Research Laboratories. “We warmly welcome the EyeBio team and look forward to working together to advance Restoret for the patients who need it.”
[ad_2]
Source link
